touchCONGRESS

Advances in the role of BCMA-targeting agents in multiple myeloma: An update from the EHA Congress 2021

Access to this content is not permitted for healthcare professionals based in the US.

Back to Home
Multiple Myeloma Watch Time: 64 mins

touchCONGRESS Advances in the role of BCMA-targeting agents in multiple myeloma: An update from the EHA Congress 2021

Watch this two-part activity exploring recent data for BCMA-targeting agents in multiple myeloma. Filmed following the European Hematology Association 2021 Virtual Congress.

Part 1: Watch multiple myeloma expert Dr María-Victoria Mateos review key data from the EHA2021 Virtual Congress Watch Now
Part 2: Choose from leading experts who discuss what these data may mean for global and regional practice Select An Interview

 

  • Part 1: Data Review
Next Chapter
Introduction
BCMA-targeting CAR T-cell therapies in relapsed/refractory multiple myeloma
BCMA-targeting antibody–drug conjugates in relapsed/refractory multiple myeloma
BCMA-targeting bispecific antibodies in relapsed/refractory multiple myeloma
Video Player Controls:
 
  • Part 2: Expert Interviews
Leave Feedback
Dr María-Victoria Mateos
Watch Time: 08:57
University of Salamanca, Salamanca, Spain

María-Victoria Mateos considers the latest data on BCMA-targeting agents for the management of relapsed/refractory multiple myeloma from the EHA2021 Virtual Congress.

 
 
Dr Heather Sutherland
Watch Time: 15:28
Vancouver General Hospital, Vancouver, BC, Canada

Heather Sutherland considers the latest data on BCMA-targeting agents for the management of relapsed/refractory multiple myeloma from the EHA2021 Virtual Congress.

 
Prof. Dr. Niels van de Donk
Watch Time: 14:13
Amsterdam University Medical Center, Amsterdam, The Netherlands

Niels van de Donk considers the latest data on BCMA-targeting agents for the management of relapsed/refractory multiple myeloma from the EHA2021 Virtual Congress.

 
 
Please Select A Video:
Leave Feedback
Overview & Learning Objectives
Overview

Stay up to date with the latest data for BCMA-targeting agents in the treatment of multiple myeloma in this two-part activity. Filmed following the EHA2021 Virtual Congress.

Learning Objectives

After watching this activity, participants should be better able to:

  • Recall efficacy data for BCMA-targeting agents in the treatment of multiple myeloma
  • Describe the safety data for BCMA-targeting agents in the treatment of multiple myeloma
  • Discuss how the latest data on BCMA-targeting agents may affect the management of patients with multiple myeloma
Register to touchONCOLOGY for FREE
  • Peer-reviewed journals and expert opinions
  • Interactive CME and e-learning modules
  • Video conference highlights
Register For Free Now

This content is intended for healthcare professionals only. Please confirm that you are a healthcare professional.

Accept Decline
Feedback Close
Feedback

Please provide feedback for this touchCONGRESS on the following
(scale 1-5, 1 strongly disagree; 5 strongly agree):

* = Mandatory Field

Feedback Close
Copied to clipboard!
accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72